Vtv Therapeutics Inc- Cl A (VTVT) Institutional Buying & Selling Tracker (Q2 2026)

VTVT ranks #6453 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

VTVT is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

45 institutions disclose a position in VTVT, but none treat it as a major bet — even Samsara BioCapital, LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Farther Finance Advisors, LLC has trimmed its VTVT position for two straight quarters, cutting it by $2.7K while still holding $8.7K.

VTVT is down 3.8% today, but institutions show net buying of $6.1M this quarter — a divergence between today's price move and the underlying institutional flow.

VTVT reported a net loss of $4.8M over the trailing twelve months.

• Not yet profitable — net loss of $4.8M over the trailing twelve months
• Revenue grew 216600.0% year over year
• Net income improved year over year, from -$19.6M to -$4.8M
• Operating cash flow was negative, using $25.3M in cash
• Current ratio of 13.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.40x equity — within a conventional range